Expert Ratings for Spruce Biosciences
Portfolio Pulse from Benzinga Insights
Spruce Biosciences (NASDAQ:SPRB) has received positive analyst ratings in the last quarter, with 1 bullish and 3 somewhat bullish ratings. The average 12-month price target for the company, according to 4 analysts, is $8.5, marking a 21.43% increase over the past month.
August 16, 2023 | 3:00 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Spruce Biosciences has received positive analyst ratings, which could potentially boost its stock price in the short term.
Analyst ratings often influence investor sentiment and can impact a company's stock price. In this case, Spruce Biosciences has received predominantly positive ratings, which could lead to an increase in its stock price in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100